Medivir AB

Company Profile

• Business description

  Medivir AB develops therapies targeting diseases with high unmet medical need. The group's drug candidates focus on indications where current treatment options are limited or non-existent, offering the potential to deliver meaningful improvements for patients. Its two programs are fostrox, designed to target liver cancer cells while minimizing side effects selectively, and MIV-711, aimed at treating Osteogenesis Imperfecta (Brittle bone disease) and Legg-Calve-Perthes disease (Perthes disease). It has developed two pharmaceutical products: Xerclear, used for treating labial herpes (cold sores), and Olysio, which have reached the market. It also has four out-licensed projects, Xerclear, MIV-701, MBLI/MET-X, and remetinostat. Geographic revenue is generated from Europe and other regions.

• Contact

  Lunastigen 5
  PO Box 1086, 2nd floor
  Huddinge141 22
  SWE

  T: +46 854683100

  E: [email protected]

  https://www.medivir.com

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Biotechnology

  Fiscal Year End

  31 December 2026

  Employees

  7